The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Ribosomal Protein L11 Negatively Regulates Oncoprotein MDM2 and Mediates a p53-Dependent Ribosomal-Stress Checkpoint Pathway
Open accessAbstract
The gene encoding p53 mediates a major tumor suppression pathway that is frequently altered in human cancers. p53 function is kept at a low level during normal cell growth and is activated in response to various cellular stresses. The MDM2 oncoprotein plays a key role in negatively regulating p53 activity by either direct repression of p53 transactivation activity in the nucleus or promotion of p53 degradation in the cytoplasm. DNA damage and oncogenic insults, the two best-characterized p53-dependent checkpoint pathways, both activate p53 through inhibition of MDM2. Here we report that the human homologue of MDM2, HDM2, binds to ribosomal protein L11. L11 binds a central region in HDM2 that is distinct from the ARF binding site. We show that the functional consequence of L11-HDM2 association, like that with ARF, results in the prevention of HDM2-mediated p53 ubiquitination and degradation, subsequently restoring p53-mediated transactivation, accumulating p21 protein levels, and inducing a p53-dependent cell cycle arrest by canceling the inhibitory function of HDM2. Interference with ribosomal biogenesis by a low concentration of actinomycin D is associated with an increased L11-HDM2 interaction and subsequent p53 stabilization. We suggest that L11 functions as a negative regulator of HDM2 and that there might exist in vivo an L11-HDM2-p53 pathway for monitoring ribosomal integrity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113 · cited 2×
“Accumulating evidence has identified the Mdm2 proto-oncogene as a major regulator of p53 (26, 29).”
BackgroundKo, L. J., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.9.1054 · Cited by 2,344
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
Zhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626
Self-citationPomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521 · cited 1×
“The 491 residues of HDM2 can be divided into three functional domains: an N-terminal region which binds p53, a Cterminal RING finger domain that promotes p53 ubiquitination, and a central region of approximately 300 residues that contains multiple sites for binding and regulation by different proteins, including RB (1…”
Background
Cited by
The p53 pathway: positive and negative feedback loops
Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967
Kruse, J.-P., & Gu, W. (2009) · Cell · doi:10.1016/j.cell.2009.04.050 · Cited by 1,610
MYC as a regulator of ribosome biogenesis and protein synthesis
van Riggelen, J., Yetil, A., & Felsher, D. W. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2819 · Cited by 956
p53 ubiquitination: Mdm2 and beyond
Brooks, C. L., & Gu, W. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.020 · Cited by 924
Ribosome biogenesis in cancer: new players and therapeutic avenues
Pelletier, J., Thomas, G., & Volarević, S. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.104 · Cited by 812
Ribosomopathies: human disorders of ribosome dysfunction
Narla, A., & Ebert, B. L. (2010) · Blood · doi:10.1182/blood-2009-10-178129 · Cited by 809
How Common Are Extraribosomal Functions of Ribosomal Proteins?
Warner, J. R., & McIntosh, K. B. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.03.006 · Cited by 747
Ribosomal proteins: functions beyond the ribosome
Zhou, X., Liao, W.-J., Liao, J.-M., Liao, P., & Lu, H. (2015) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjv014 · Cited by 743
Regulation of p53 Translation and Induction after DNA Damage by Ribosomal Protein L26 and Nucleolin
Takagi, M., Absalon, M. J., McLure, K. G., & Kastan, M. B. (2005) · Cell · doi:10.1016/j.cell.2005.07.034 · Cited by 663
Signaling to p53: ribosomal proteins find their way
Zhang, Y., & Lu, H. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.024 · Cited by 591
Self-citationBywater, M. J., Poortinga, G., Sanij, E., Hein, N., Peck, A., Cullinane, C., Wall, M., Cluse, L., Drygin, D., Anderes, K., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.019 · Cited by 563
Pathophysiology and management of inherited bone marrow failure syndromes
Shimamura, A., & Alter, B. P. (2010) · Blood Reviews · doi:10.1016/j.blre.2010.03.002 · Cited by 552
Inhibition of MDM2-mediated p53 Ubiquitination and Degradation by Ribosomal Protein L5
Dai, M.-S., & Lu, H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403722200 · Cited by 534
Coping with stress: multiple ways to activate p53
Horn, H. F., & Vousden, K. H. (2007) · Oncogene · doi:10.1038/sj.onc.1210263 · Cited by 522
Šulić, S., Panić, L., Barkić, M., Merćep, M., Uzelac, M., & Volarević, S. (2005) · Genes & Development · doi:10.1101/gad.359305 · Cited by 510
Dai, M.-S., Zeng, S. X., Jin, Y., Sun, X.-X., David, L., & Lu, H. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.17.7654-7668.2004 · Cited by 489
The RNA Polymerase I Transcription Machinery: An Emerging Target for the Treatment of Cancer
Drygin, D., Rice, W. G., & Grummt, I. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105844 · Cited by 418
Gazda, H. T., Sheen, M. R., Vlachos, A., Choesmel, V., O'Donohue, M.-F., Schneider, H., Darras, N., Hasman, C., Sieff, C. A., Newburger, P. E., et al. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.11.004 · Cited by 417
Kurki, S., Peltonen, K., Latonen, L., Kiviharju, T. M., Ojala, P. M., Meek, D., & Laiho, M. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00110-2 · Cited by 416
The MDM2-p53 pathway revisited
Subhasree, N., Jiangjiang, Q., Kalkunte, S., Minghai, W., & Ruiwen, Z. (2013) · The Journal of Biomedical Research · doi:10.7555/jbr.27.20130030 · Cited by 414
Dutt, S., Narla, A., Lin, K., Mullally, A., Abayasekara, N., Megerdichian, C., Wilson, F. H., Currie, T., Khanna-Gupta, A., Berliner, N., et al. (2011) · Blood · doi:10.1182/blood-2010-07-295238 · Cited by 410
Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy
Kang, J., Brajanovski, N., Chan, K. T., Xuan, J., Pearson, R. B., & Sanij, E. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00728-8 · Cited by 408
Inhibition of HDM2 and Activation of p53 by Ribosomal Protein L23
Jin, A., Itahana, K., O'Keefe, K., & Zhang, Y. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.17.7669-7680.2004 · Cited by 353
Self-citationActivating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL
Tzoneva, G., Perez-Garcia, A., Carpenter, Z., Khiabanian, H., Tosello, V., Allegretta, M., Paietta, E., Racevskis, J., Rowe, J. M., Tallman, M. S., et al. (2013) · Nature Medicine · doi:10.1038/nm.3078 · Cited by 350
PML regulates p53 stability by sequestering Mdm2 to the nucleolus
Bernardi, R., Scaglioni, P. P., Bergmann, S., Horn, H. F., Vousden, K. H., & Pandolfi, P. P. (2004) · Nature Cell Biology · doi:10.1038/ncb1147 · Cited by 347
The Mdm2–p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor
Manfredi, J. J. (2010) · Genes & Development · doi:10.1101/gad.1941710 · Cited by 344
“These include the ribosomal proteins RPL5, RPL11, RPL23, and RPS7 (Lohrum et al. 2003; Zhang et al. 2003; Dai et al. 2004; Zhu et al. 2009), as well as nucleophosmin (NPM) (Colombo et al. 2002) and nucleostemin (NS) (Dai et al. 2008).”
BackgroundRNA polymerases I and III, growth control and cancer
White, R. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1551 · Cited by 333
Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells
Yang, Y., Ludwig, R. L., Jensen, J. P., Pierre, S. A., Medaglia, M. V., Davydov, I. V., Safiran, Y. J., Oberoi, P., Kenten, J. H., Phillips, A. C., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.029 · Cited by 322
Ribosome biogenesis surveillance: probing the ribosomal protein-Mdm2-p53 pathway
Deisenroth, C., & Zhang, Y. (2010) · Oncogene · doi:10.1038/onc.2010.189 · Cited by 302
Self-citationThe Roles of MDM2 and MDMX in Cancer
Karni-Schmidt, O., Lokshin, M., & Prives, C. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040349 · Cited by 296
Nucleolar stress with and without p53
James, A., Wang, Y., Raje, H., Rosby, R., & DiMario, P. (2014) · Nucleus · doi:10.4161/nucl.32235 · Cited by 285
Nucleolar Stress: hallmarks, sensing mechanism and diseases
Yang, K., Yang, J., & Yi, J. (2018) · Cell Stress · doi:10.15698/cst2018.06.139 · Cited by 283
MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation
Wang, C., Ivanov, A., Chen, L., Fredericks, W. J., Seto, E., Rauscher, F. J., & Chen, J. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600791 · Cited by 263
Chen, D., Zhang, Z., Li, M., Wang, W., Li, Y., Rayburn, E. R., Hill, D. L., Wang, H., & Zhang, R. (2007) · Oncogene · doi:10.1038/sj.onc.1210327 · Cited by 261
The role of human ribosomal proteins in the maturation of rRNA and ribosome production
Robledo, S., Idol, R. A., Crimmins, D. L., Ladenson, J. H., Mason, P. J., & Bessler, M. (2008) · RNA · doi:10.1261/rna.1132008 · Cited by 259
mTORC1 signaling controls multiple steps in ribosome biogenesis
Iadevaia, V., Liu, R., & Proud, C. G. (2014) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2014.08.004 · Cited by 248
The Ribosome Biogenesis—Cancer Connection
Penzo, M., Montanaro, L., Treré, D., & Derenzini, M. (2019) · Cells · doi:10.3390/cells8010055 · Cited by 242
“[42] and Dai and Lu [43], who demonstrated that the p53 stabilization induced by inhibited rRNA synthesis was due to the fact that the ribosomal proteins L11-uL5 and L5-uL18, no longer used for ribosome building, bind to HDM2 thus preventing HDM2-mediated p53 ubiquitination and degradation.”
BackgroundThe ribosomal basis of diamond-blackfan anemia: mutation and database update
Boria, I., Garelli, E., Gazda, H. T., Aspesi, A., Quarello, P., Pavesi, E., Ferrante, D., Meerpohl, J. J., Kartal, M., Da Costa, L., et al. (2010) · Human Mutation · doi:10.1002/humu.21383 · Cited by 233
“RPL11 also cooperates with RPL5 to inhibit the E3 ubiquitin ligase activity of MDM2, thus resulting in the accumulation of transcriptionally active p53 [Zhang et al., 2003].”
The role of ubiquitin modification in the regulation of p53
Hock, A. K., & Vousden, K. H. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.05.022 · Cited by 168
MDMX regulation of p53 response to ribosomal stress
Gilkes, D. M., Chen, L., & Chen, J. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601424 · Cited by 142
“Recent studies revealed a connection between ribosomal stress and p53-dependent cell cycle arrest, suggesting that aberrant rRNA and ribosome biogenesis are sensed by p53 (Marechal et al, 1994; Pestov et al, 2001; Lohrum et al, 2003; Zhang et al, 2003).”
BackgroundInfluentialRegulation of MDMX nuclear import and degradation by Chk2 and 14-3-3
LeBron, C., Chen, L., Gilkes, D. M., & Chen, J. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601032 · Cited by 122
Regulation of MDMX Expression by Mitogenic Signaling
Gilkes, D. M., Pan, Y., Coppola, D., Yeatman, T., Reuther, G. W., & Chen, J. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01633-07 · Cited by 82
Meek, D. W., & Hupp, T. R. (2010) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.10.005 · Cited by 76
The p53 response: Emerging levels of co-factor complexity
Coutts, A. S., & La Thangue, N. B. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.150 · Cited by 72
Hubackova, S., Davidova, E., Boukalova, S., Kovarova, J., Bajzikova, M., Coelho, A., Terp, M. G., Ditzel, H. J., Rohlena, J., & Neuzil, J. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2224-7 · Cited by 58
The roles of MDM2 and MDMX phosphorylation in stress signaling to p53
Chen, J. (2012) · Genes & Cancer · doi:10.1177/1947601912454733 · Cited by 33
Metadata
- Authors
- Zhang, Y., Wolf, G. W., Bhat, K., Jin, A., Allio, T., Burkhart, W. A., & Xiong, Y.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2003-12-01
- Volume
- 23
- Issue
- 23
- Pages
- 8902-8912
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2112706571
- Cited by
- 558
- References
- 52
- FWCI
- 8.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.